creat bluematrix
oric buy ignyt ing -a pipelin overcom resist cancer
initi buy rate pt
messag initi coverag oric buy rate pt oric focus discov develop small
molecul therapeut goal overcom resist cancer compani assembl fulli integr drug discoveri
develop team signific pedigre leverag expertis within three specif area hormone-depend cancer
precis oncolog key tumor depend lead product candid select antagonist glucocorticoid
receptor gr oric main near-term valu driver current undergo phase ib clinic trial prostat cancer solid
tumor clinic updat guid oric also oral inhibitor preclin develop target
key compon receptor pathway think could potenti benefit addit extern clinic valid
come year valu oric per share support probability-adjust forecast
rate oric buy price target clinical-stag biopharmaceut
compani focus develop innov therapi counter resist mechan cancer within three specif area hormone-
depend cancer eg prostat cancer breast cancer etc precis oncolog eg util biomark patient select key
tumor depend eg driver mutat synthet lethal etc compani manag team founder signific
pedigre area oncolog drug develop multipl team member work togeth previous ignyta mediv
aragon seragon genentech play key role develop fda-approv drug includ erleada xtandi
gleevec sprycel well rozlytrek view significantli reduc d/execut risk current pipelin candid
includ gr antagonist current phase ib clinic trial develop base work conduct laboratori
dr sawyer mskcc search explanatori factor underli resist anti-androgen prostat cancer therapi well
oral bioavail inhibitor key compon adenosin pathway hypothes reduc
effect certain chemotherapy- immunotherapy-bas treatment addit oric multipl addit preclinci
oncolog program discoveri stage base-cas valuat deriv probability-of-success po -adjust
estim prostat cancer pos-adjust estim solid tumor well cash expect year
upsid scenario show compel clinic product profil believ oric could valu
share wherea downsid scenario estim oric could worth ye
could best-in-class gr inhibitor address signific commerci opportun treatment-resist prostat
cancer potent select small molecul antagonist glucocorticoid receptor gr
link resist multipl class cancer therapeut across varieti solid tumor base interview kol
think mechanist data particularli intrigu prostat cancer gr signal shown bypass mechan
anti-androgen therapi gr take ar signal increas express gr prostat cancer correl
resist xtandi pfe/alpmi well wors outcom clinic trial gr also studi potenti role mediat
resist chemotherapi case mechan appear relat gr role impart pro-surviv phenotyp
tumor correl poor prognosi patient er-neg breast cancer treat chemotherapi separ
think clinic data present competitor provid addit increment extern clinic valid
concept gr inhibit oncolog undergon phase safeti dose-escal studi healthi volunt
well toler pd market indic on-target gr inhibit drug current two phase ib combin dose-
page analyst certif import disclosur
escal studi one combin xtandi metastat prostat cancer part clinic trial collabor astella one
combin abraxan advanc metastat solid tumor updat data guid disclosur current
assum success probabl forecast unadjust us peak sale opportun prostat cancer
commerci launch base case scenario also forecast potenti sale cancer combin
abraxan adjust po launch
preclin agent could potenti receiv addit extern valid target adenosin pathway
product clinic data pend ind file oric second product candid oral bioavail
small molecul inhibitor part adenosin pathway believ play import role resist chemotherapy-
immunotherapy-bas treatment regimen three key target within adenosin pathway pursu sever
biopharmaceut compani enzym control rate extracellular adenosin
produc overexpress associ poor prognosi sever cancer number inhibitor enter
tcon imab nearli monoclon antibodi iv-administ small molecul clinic updat
agent later year next could potenti provid addit extern valid think well posit
first oral bioavail potent small molecul inhibitor develop oric plan file ind investig
new drug current attribut valu preclin program posit data
competitor program could valid effect therapeut target immuno-oncolog could potenti sourc
longer term upsid
upcom potenti stock catalyst pipelin event current evalu two phase ib dose escal
cohort one combin xtandi mcrpc patient one combin abraxan patient solid tumor oric
expect determin recommend phase dose initi expans cohort interim efficaci translat
data cohort guid one first half second half competitor cort gr inhibitor
relacoril random phase ii studi line platinum-resist ovarian cancer top-lin result guid
ind file plan
page analyst certif import disclosur
initi coverag oric
page analyst certif import disclosur
tabl content
compani profil execut summari
vi opportun taxan refractori solid tumor
page analyst certif import disclosur
page analyst certif import disclosur
rate oric buy oric focus discov
develop small molecul therapeut goal overcom
resist cancer compani assembl fulli integr
drug discoveri develop team signific pedigre
leverag expertis within three specif area hormone-
depend cancer precis oncolog key tumor
antagonist glucocorticoid receptor gr oric main near-
term valu driver current undergo phase ib clinic trial
prostat cancer solid tumor clinic updat guid
valu oric per share support
probability-adjust forecast
probabl success po prostat
cancer solid tumor
competit posit vs gr inhibitor
clinic develop relacoril exicoril
market potenti prostat cancer
potenti extern valid clinic profil competit
posit oric inhibitor
select phase ib studi
enzalutamid nab-paclitaxel initi dose-
interim efficaci translat data dose
expans cohort enzalutamid nab-
paclitaxel one
ind fill inhibitor
page analyst certif import disclosur
chart slide overal market perform
oric emerg biopharmaceut compani focus discov develop small molecul
therapeut goal overcom resist cancer compani assembl fulli integr drug discoveri develop team
leverag expertis within three specif area hormone-depend cancer precis oncolog key tumor depend
lead product candid potent select antagonist glucocorticoid receptor gr gr link resist
multipl class cancer drug across varieti solid tumor complet phase studi healthi subject current phase ib
trial combin xtandi metastat prostat cancer abraxan advanc metastat solid tumor interim data
guid respect
oric second product candid oral bioavail small molecul inhibitor ind file guid part
adenosin pathway believ play role resist chemotherapy- immunotherapy-bas treatment regimen oric also develop
multipl addit precis medicin target hallmark cancer resist mechan
page analyst certif import disclosur
platform support success founder
high pedigre founder advisor manag team
track record success
multi-billion commerci opportun prostat cancer
high-valu target potenti de-risk competitor data
year next
target go big market remain
unvalid novel target remain risk
may limit singl agent activ
make interpret earli clinic data challeng
busi competit landscap target adenosin
fulli integr platform experienc leadership oric
manag team founder signific pedigre area
oncolog drug discoveri develop multipl team member
work togeth previous ignyta mediv aragon seragon
genentech play key role develop fda-approv
drug includ erleada xtandi gleevec sprycel well rozlytrek
view significantli reduc d/execut risk
could best-in-class gr inhibitor address
signific commerci opportun treatment-resist prostat
cancer base interview kol think mechanist
data particularli intrigu prostat cancer gr signal
shown bypass mechan anti-androgen therapi gr
take ar signal increas express gr prostat
cancer correl resist xtandi pfe/alpmi well
wors outcom clinic trial current assum success
probabl forecast unadjust us peak sale
opportun prostat cancer commerci launch base
valid target adenosin pathway product clinic
data pend ind file oral bioavail
small molecul inhibitor part adenosin pathway believ
play import role resist chemotherapy- immunotherapy-
base treatment regimen number inhibitor enter
crv novn surf tcon
imab clinic updat agent later year next could
potenti provid addit extern valid
think well posit first oral bioavail potent small
molecul inhibitor ind plan
page analyst certif import disclosur
per dcf
mcap wacc termin growth line
assumpt biotech compani without clinic
proof concept
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
po enzalutamid
po nab-paclitaxel solid
posit efficaci readout
enzalutamid clean safeti po increas
posit efficaci readout
nab-paclitaxel clean safeti po increas
disappoint readout phase
ib expans cohort po prostat
cancer reduc po solid tumor
reduc
page analyst certif import disclosur
oric platform focus address unmet need resist
overview oric cancer resist platform
oric build portfolio novel agent target multipl resist mechan includ innat
resist acquir resist bypass resist
oric founder manag team decades-long heritag identifi character
resist mechan oncolog special expertis
hormone-depend cancer dr charl sawyer inventor erleada dr richard heyman co-
founder seragon
precis oncolog manag team prior experi ignyta develop rozlytrek dr
sawyer pivot role develop gleevec sprycel
tumor depend chief scientif offic head drug discoveri head biolog
head translat medicin recent work genentech develop cotel zelboraf polivi
guggenheim secur llc imag oric fill
page analyst certif import disclosur
oric pipelin focus small molecul product candid
address resist mechan cancer treatment
oric pipelin candid develop stage
page analyst certif import disclosur
mskcc hhmi investig
former cfo ignyta acquir
role discoveri develop gleevec
prior role tpg capit mckinsey
sprycel xtandi erleada
member nation academi scienc
board member novarti
board member turn
former ceo/found aragon acquir
former head translat oncolog genentech
former ceo/found seragon acquir
former director signal transduct
board member gritston vividion metacrin
inventor issu patent author peer-
mskcc hhmi investig
chair cancer biolog genet cancer research
mskcc
former ignyta
former
expert tumor network molecular determin
board member erasca
page analyst certif import disclosur
guggenheim balanc sheet forecast
page analyst certif import disclosur
michael schmidt incom statement sales- royalty- total revenues- cogs- total cost oper incom interest incom incom expens incom loss net incom incom tax- net incom basic ep per dilut ep per share outstand share outstand dilut bs cf short-term guggenheim secur llc estim sec file
page analyst certif import disclosur
glucocorticoid receptor gr belong
nuclear hormon receptor famili also
receptor pr androgen receptor ar
glucocorticoid steroid hormon
secret adren gland
circadian stress-associ manner
regul metabol cell growth
apoptosi differenti
glucocorticoid signal
superfamili nuclear receptor
express across wide varieti
nuclear transloc nucleu gr
bind glucocorticoid respons
element dna transcript
activ spectrum gene
guggenheim secur llc imag oric fill
page analyst certif import disclosur
gr overexpress associ wors outcom variou type
percentag gr cell higher
meta-analysi data clinic
good respond xtandi
month benefit xtandi treatment
bad respond month
benefit xtandi treatment base
post hoc analysi clinic studi
studi earli breast cancer
high level gr express
significantli correl shorter
relapsed-free-surviv er-pati
treat chemotherapi
gr express level evalu
patient ovarian cancer
median significantli
decreas case high gr
month compar
guggenheim secur llc imag oric fill
page analyst certif import disclosur
potenti mechan gr-associ resist cancer therapi
gr mediat resist xtandi prostat
cancer potenti take ar signal
gr may also mediat resist chemotherapi
though emt anti-apoptosi gene express
demonstr gr signal bypass mechan
anti-androgen therapi gr take ar signal
increas express gr prostat cancer
correl resist xtandi
gr also studi potenti role mediat
resist chemotherapi though case
mechan appear relat gr role impart
pro-surviv phenotyp tumor via certain biolog
potenti yap mol
cell biol etc anti-apoptosi eg
guggenheim secur llc imag oric fill
page analyst certif import disclosur
gr over-express broad rang tumor type
gr express variou type cancer
assay analyz sampl
nuclear stain report base h-
percent stain
least carcinoma cell record
cancer evalu melanoma renal cell
carcinoma sarcoma head neck cancer
prostat cancer cervic cancer
gr over-express
guggenheim secur llc imag oric fill
page analyst certif import disclosur
page analyst certif import disclosur
revers gr-driven enzalutamid resist pre-clin
androgen inhibitor treatment led resist lncap
xenograft model exogen ar overexpress
resist correl increas gr mrna
ar inhibit enzalutamid upregul gr prostat
guggenheim secur llc imag oric fill
page analyst certif import disclosur
overcom gr-driven resist chemotherapi
vitro across human cancer cell line
overcom gr-driven resist
chemotherapi vivo tnbc xenograft model
guggenheim secur llc imag oric fill
page analyst certif import disclosur
page analyst certif import disclosur
evalu combin either xtandi abraxan
solid tumor includ pancreat ovarian tnbc
page analyst certif import disclosur
singl agent well toler phase ia safeti
evalu total healthi volunt includ treat singl ascend dose
treat multipl ascend dose mg
singl agent safeti profil healthi volunt
pain extrem
advers event observ across phase ia studi limit grade higher rate gi event mg attribut
least part pill burden earli clinic formul capsul
page analyst certif import disclosur
effect block gr pathway signal demonstr
chang key biomark
pharmacokinet pk profil
healthi volunt
pharmacodynam pd measur gr inhibit oric-
key biomark
exposur cmax auc
plasma increas dose-depend manner
approxim accumul
half-lif hour support once-daili
treatment associ
chang key pd biomark support
on-target activ includ increas
plasma cortisol level decreas gene
express downstream gr signal
pathway
guggenheim secur llc imag oric fill
page analyst certif import disclosur
page analyst certif import disclosur
overview prostat cancer natur histori treatment paradigm us
page analyst certif import disclosur
synthesi bind androgen receptor ar
therapeut target hormon therapi prostat cancer
lhrh agonist
guggenheim secur llc imag adapt compani present
gene
page analyst certif import disclosur
global opportun second-gener hormon therapi believ
surpass bn even zytiga get patent recent
histor sale consensu estim sale new hormon therapi prostat cancer
guggenheim secur llc estim consensu evaluatepharma
page analyst certif import disclosur
induc gr overexpress one potenti mechan
underli resist xtandi treatment prostat cancer
terrain studi compar xtandi
bicalutamid front line mcrpc
model gr induct resist tissu
enzalutamid bicalutamid mcrpc
preclin find support model subset
prostat cancer cell prime gr induct
context ar inhibit adapt resist
tail radiolog around indic
cell clonal expand select
half patient treat xtandi eventu relaps
guggenheim secur llc imag oric fill
pressur ar blockad eventu emerg drug-
ar-driven tumor driven gr
page analyst certif import disclosur
analysi clinic data suggest potenti role gr mediat xtandi
resist prostat cancer
posit correl gr express poor respons xtandi
post hoc analysi clinic studi prostat cancer patient poor respons ar
antagonist xtandi defin month benefit xtandi treatment declin
higher express level gr defin percentag gr cell suggest potenti
role gr downstream signal xtandi resist
guggenheim secur llc imag oric fill
page analyst certif import disclosur
subgroup analysi xtandi phase studi also indic
potenti role gr xtandi resist
investig analysi mdvn phase clinic trial affirm patient mcrpc
previous receiv docetaxel random receiv enzalutamid placebo highlight potenti role gr
mediat enzalutamid resist
post hoc analysi evalu impact baselin corticosteroid use clinic outcom patient
patient trial corticosteroid baselin
result demonstr patient baselin corticosteroid gr agon faster time progress
decreas overal surviv adjust prognost factor age perform statu prior therapi
overal surviv patient corticosteroid
overal surviv patient without
guggenheim secur llc imag oric fill
page analyst certif import disclosur
evalu combin either xtandi prostat
solid tumor includ pancreat ovarian tnbc
page analyst certif import disclosur
on-going phase ib studi evalu xtandi chemo-
nave mcrpc patient progress xtandi set
mpc patient diseas progress xtandi previous treat chemotherapi second-gener
dose expans stratif baselin gr express level use
safeti pk pd initi evid clinic activ declin imag ctc convers
exploratori data gener archiv tumor tissu pre- post-and end-of-treat biopsi blood
trial initi interim efficaci translat data guid
march dose level mg mg xtandi enrol complet two patient
complet cycl day without dlt event current cycl cycl respect one addit
patient on-going cycl
guggenheim secur llc imag oric fill
page analyst certif import disclosur
benchmark phase ib studi
efficaci select drug mcrpc progress xtandi treatment
time
mcrpc patient treat zytiga progress xtandi
mcrpc patient treat zytiga zytiga xtandi progress xtandi
mcrpc patient treat either altern androgen receptor target art agent cabazitaxel progress art agent
docetaxel docetaxel castrate-sensit set consid one prior exposur
mcrpc patient treat lynparza treatment androgen receptor target agent chemotherapi
page analyst certif import disclosur
potenti opportun move earlier line
enzalutamide/androgen receptor target therapi prostat cancer
clinic studi evalu new antiandrogen agent earli prostat cancer
time
year
year
year
year
year
year
year
page analyst certif import disclosur
oric establish clinic trial collabor astella
combin xtandi prostat cancer
oric conduct phase studi cost
astella respons provid enzalutamid select regulatori pharmacovigil activ cost oric
oric may disclos clinic studi data third parti confidenti time enter type busi
arrang regard time
astella right announc publish data agreement
requir futur collabor astellas/pf beyond phase studi
oric control intellectu properti ip relat combin enzalutamid
astella receiv licens use combin ip gener studi relat enzalutamid
page analyst certif import disclosur
opportun taxan refractori solid
page analyst certif import disclosur
evalu combin abraxan phase ib studi
patient advanc solid tumor
solid tumor includ pancreat ovarian tnbc
page analyst certif import disclosur
on-going phase ib evalu abraxan patient
dose escal enrol limit baselin gr statu
dose expans taxane-refractori patient select solid tumor base upon baselin gr statu
safeti pk pd initi evid clinic activ
exploratori data gener archiv tumor tissu pre- post-and end-of-treat biopsi blood
select initi expans cohort expect interim efficaci translat data expect oric
guggenheim secur llc imag oric fill
page analyst certif import disclosur
abraxan ph ib trial progress dose adjust
dose schedul abraxan combo regimen
day
march patient enrol studi across dose cohort
initi cohort mg nab-paclitaxel exceed maximum toler dose combo regimen
patient advanc pancreat cancer enrol first cycl treatment patient experienc dlt specif
one patient experienc grade fatigu discontinu treatment two week studi second patient liver metastas
experienc grade neutropenia thrombocytopenia grade hepat failur set rapid diseas progress
toxic well-describ nab-paclitaxel includ report hepat necrosi hepat encephalopathi lead death
metabol primarili via liver
base recommend safeti review committe dose escal restart lower dose addit
prophylact growth factor g-csf potenti nab-paclitaxel-induc neutropenia requir
dose level mg nab-paclitaxel patient one endometri cancer one colorect cancer
one poorli differenti neuroendocrin carcinoma lung enrol patient complet dlt evalu period
dose level mg nab-paclitaxel patient one gastric cancer one larg cell neuroendocrin
carcinoma lung one testicular cancer complet dlt evalu period without dlt event
dose level mg nab-paclitaxel two new patient enrol
page analyst certif import disclosur
one patient partial respons on-going ph ib dose escal
combin abraxan
endometri cancer patient reduct tumor burden cycl eight week studi shown
ct scan tumor marker also declin u/ml baselin u/ml
patient experienc grade revers
chest ct scan baselin end cycl
colorect cancer patient evid gr-posit stain baselin went treatment diseas
progress seven week
patient poorli differenti neuroendocrin carcinoma lung unknown gr statu went
treatment diseas progress week
patient gastric cancer treatment cycl
patient larg cell lung cancer treatment cycl
patient testicular cancer went treatment diseas progress end cycl
guggenheim secur llc imag oric fill
page analyst certif import disclosur
abraxan well toler far
treatment-rel ar occur patient grade sever
guggenheim secur llc imag oric fill
page analyst certif import disclosur
